At the news
? BULLISHIMPACT 6/10 6-K filed Jun 30, 2026 at 16:05 ET
Ascendis Pharma announced Week 104 radiographic data from the pivotal ApproaCH trial of TransCon CNP (navepegritide) in achondroplasia, showing continued improvements in lower extremity alignment (tibial-femoral angle) through two years with a favorable safety profile. The data reinforce the drug's disease-modifying potential and support regulatory advancement.
- TransCon CNP-treated children showed mean TFA improvement of -2.2 degrees over two years (baseline 9.1° to 6.9° at Week 104).
- In children with baseline TFA ≥5° (genu varum), mean TFA improved -3.8 degrees over two years (13.4° to 9.6°).
- Placebo-switch group showed TFA improvement of -1.7 degrees during the 52-week open-label extension.
- Mean TFA Z-score decreased from 3.62 at baseline to 2.96 at Week 104 in the continuous-treatment group.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access